Anti-Human CTLA-4 (Ipilimumab) - Fc Muted™ HRP
£379.69
Anti-Human CTLA-4 (Ipilimumab) - Fc Muted™ HRP (LT1607-100ug)
Product
| Cat # LT1607-100ug | Size 100 µg |
Price
£379.69
|
Qty
|
Description
Cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) is a protein receptor that serves as an immune checkpoint and down-regulates the immune system. CTLA-4 is constitutively expressed in regulatory T cells but is only upregulated in conventional T cells following activation. Many cancers, including Melanoma, are associated with CTLA-4 upregulation because the body’s ability to recognize and destroy cancer cells is hampered by an inhibitory mechanism. Ipilimumab targets CTLA-4 and works by turning off this inhibitory mechanism and, thus, enhances the body’s own immune response against cancer cells.”2 Emerging research suggests that combined blockade of PD-1 and CTLA-4, with Nivolumab and Ipilimumab respectively, could produce greater antitumor activity than blockade of either pathway alone.1 This cost-effective, research-grade Anti-Human CTLA-4 (Ipilimumab) utilizes the same variable regions from the therapeutic antibody Ipilimumab making it ideal for research projects.
Specifications
| Manufacturer | Leinco Technologies Inc |
|---|---|
| Manufacturer Cat# | LT1607 |
| Product Size | 100 µg |
| Concentration | 0.5 mg/ml |
| Formulation | This HRP-conjugated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4, 1% BSA. (Warning: Use of sodium azide as a preservative will inhibit the enzyme activity of horseradish peroxidase) |
| Clone | MDX-010 |
| Target | CTLA-4 |
| Applications | ELISA, FC |
| Antigen | CTLA4 is constitutively expressed in regulatory T cells. |
| Storage | This horseradish peroxidase conjugated monoclonal antibody is stable when stored at 2-8°C. Do not freeze. |
| Protein | CTLA-4 |